

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: AREV Brands International Ltd. (“AREV” or the “Issuer”).

Trading Symbol: AREV

Number of Outstanding Listed Securities: 54,546,847

Date: September 2019

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer, AREV Brands International Ltd. (“AREV”), produces and delivers functional ingredients from its world-class extraction system. AREV is revolutionizing the current delivery method of coconut oil, whey protein and nutrients through emulsification. These premium ingredients and products are targeted for the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV is also working with Pharmacy and Dispensary operators with an innovative emulsified base formula to disperse Cannabis oil extracts from specific selected genetic Cannabis strains that address 5 areas of health including Anxiety, Pain Management, Insomnia, Central Nervous System Disorders & Libido.

2. Provide a general overview and discussion of the activities of management.

During the month of September 2019, the Company announces that it is negotiating to acquire 50 per cent of Lighthouse Genomics Inc. Lighthouse will remain an independent operating entity with voting control and an agreement to provide AREV holdings with preferential access to genomic analysis to inform AREV breeding operations with advanced genetic science.

AREV, a cannabis integrator, conducts extensive breeding research and development to produce proprietary genetic assets through its holdings in BC Bud Depot. The Lighthouse acquisition complements the Company’s purchase of its largest holding, BC Bud Depot assets, which include a seed bank considered to be a world-class genetic resource, as previously announced September 7, 2018. The strategic investment in Lighthouse Genomics Inc. strengthens AREV’s position as an international leader in cannabis genetic research and breeding.

AREV’s programs operated by BC Bud Depot will utilize Lighthouse’s proprietary technologies to accelerate breeding of new genetic assets through oversight of the genetic basis of traits in cannabis. Lighthouse’s industry-leading technologies include the Lighthouse Cannabis Assay™ (LCA), which captures 40,000 single nucleotide polymorphisms (SNPs) selected for high relevance within the cannabis genome. The LCA is considered the most comprehensive SNP genotype array chip for cannabis currently available worldwide. Lighthouse has also produced a

proprietary bioinformatics software pipeline to analyze and interpret data produced by LCA genotyping or by Whole Genome Sequencing. These data-capture and analytic technologies provide AREV with an unprecedented opportunity to apply strategic genomic intelligence to producing rare and stable traits in new genetic assets, developed with speed and precision far surpassing conventional plant-breeding practices.

During the month of September 2019, the Company announced that WOLLAMMO™ a BC Bud Depot product, is being packaged in preparation for sales after finalizing extensive testing on hemp and cannabis. WOLLAMMO™ is comprised of wollastonite a unique rare earth mineral composition from the Verticle Exploration St-Onge Deposit. The deposit is very high quality and clean compared to others in the world. The harvested plant biomass is being analyzed to ensure no heavy metals are present. While waiting for the final results AREV through BC Bud Depot is preparing to supply this fantastic solution to solve a problem the expanding cannabis and hemp cultivators have. The product will soon be available September 30 online at www.wollammo.com

AREV will enter into a Distribution Agreement with Vertical Exploration, whereby Vertical will supply its St-Onge wollastonite to AREV Brands for direct distribution to both small-scale craft growing operations and potentially larger-scale Health Canada approved companies directly involved in growing and processing cannabis and hemp.

During the month of September 2019, the Company announced that hat BC Bud Depot has won the Best Seedbank Award at the 2019 Grow Up Conference and Expo in Niagara Falls, Canada, held September 14th, 2019. This marks the second major first place industry award that BC Bud Depot has received in 2019, having received a Genovar Award on the merit of exceptional genetic qualities of their flagship CBD variety, CBD God.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

NONE.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

NONE.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

NONE.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

NONE.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

NONE.

8. Describe the acquisition of new customers or loss of customers.

NONE.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

NONE.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

NONE.

11. Report on any labour disputes and resolutions of those disputes if applicable.

NONE.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

NONE.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

NONE.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.
NONE.
16. Provide details of any changes in directors, officers or committee members.
NONE.
17. Discuss any trends, which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are discussed in the Issuer's financial statements (the "YE Financial Statements") and corresponding management's discussion and analysis (the "YE MD&A") for the year-ended December 31, 2018. The Q4 Financial Statements and YE MD&A are both available under the Issuer's profile on SEDAR at www.sedar.com.

Certificate Of Compliance


The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated September 30, 2019.

Mike Withrow

Name of Director or Senior Officer



Signature

CEO & Director

Official Capacity

Issuer Details		For Month End	Date of Report
Name of Issuer AREV Brands International Ltd.		September 2019	YYYY/MM/DD 2019/10/30
Issuer Address Unit 2 – 9049 Shaughnessy Street			
City/Province/Postal Code Vancouver, BC, V6P 6R9	Issuer Fax No. () n/a	Issuer Telephone No. (604) 803-8439	
Contact Name Denby Greenslade	Contact Position Corporate Secretary	Contact Telephone No. (604) 803-8439	
Contact Email Address denby@arevbrands.com	Web Site Address www.arevbrands.com		